Testing effectiveness (Phase 2)Ended earlyNCT01319539
What this trial is testing
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+11 more
National Cancer Institute (NCI) 12